The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
This will be an interesting week. I need coffee! ??
CF loves a 7am Monday RNS
Ah yes 19mins into Cathals conference call ;)
https://t.co/PoRVDURmUw
Bronxville, have you got a link to this pls mate?
"Yep and I believe I was the first 1 who said that Prep Biopharma were in discussions with a Chinese consortium about their Inhaler.."
So that valuation of $1bn by Goldman Sachs just last year is pre covid and pre phase 2 end points meeting this March. That valuation has got to be higher now...
Cathal has highlighted Merck acquiring Themis in every interview he's done recently and said he believes close to $500m was paid. He's also name dropped Novartis a few times. I think we are looking at over $500m comfortably for what is a Universal Flu Vaccine that has the potential to replace all other Flu vacs out there.
Open Orphan Chief Executive Trevor Phillips explained universal vaccine FLU-v's advantages over the typical seasonal flu vaccine are that the vaccine's composition does not change year-to-year and it is made synthetically, meaning it can be manufactured year-round.
"It will not be subject to a strict vaccination window as is the case with seasonal flu vaccines. Also, being a universal vaccine, it should provide protection against new strains of flu virus which the seasonal flu vaccine is not able to do," said Phillips.
https://www.roi-nj.com/2020/05/26/healthcare/merck-to-acquire-themis-to-develop-covid-19-vaccine/
Think when the general masses start to understand what we have, interest will grow and we re rate big time.
Not to mention the progress and move to profitability of our core business in Q3
Dont want to be to bullish but I see an SP North of 50p over the next 6 months..Oh well I have said it now
So hypothetically if they achieved a straight up sale and ORPH were to net £300m for their share there could be a special dividend of around 50p per share So 100,000 shares that would cost about £12k tomorrow could net £50k dividend if it comes off.
Yep and I believe I was the first 1 who said that Prep Biopharma were in discussions with a Chinese consortium about their Inhaler..
So Imutex validated by Goldman Sachs last year with an enterprise valuation upwards of $1bn and that was before the primary end of points of phase 2 was met in March of this, ready for Phase 3. I think i know a company that owns 49% of that looking to out right sell or list! ;-)
"Last year, Seek and Hvivo engaged Goldman Sachs to aid with a possible sale of Imutex.
Documents show that the investment bank was basing its likely fee for its services on two scenarios: Imutex having an enterprise value of up to $1bn (€902m), or more than $1bn."
Now this is huge, to have independant 3rd party validation from Goldman Sachs as recently as last year. A Universal Flu Vaccine in late stage development is going to be in quite a bit more demand than last year in this post Covid period. Cathals ORPH now owns 49% and we know they're looking to monetize this now through a sale or listing.
Source link:
https://m.independent.ie/business/irish/open-orphan-in-line-to-take-stake-in-1bn-flu-drug-38808471.html